FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2348249897> ?p ?o ?g. }

• W2348249897 endingPage "42616" @default.
• W2348249897 startingPage "42608" @default.
• W2348249897 abstract "// Wen-Yi Wang 1, 2, * , Tian-Yun Lin 3, * , Chih-Wen Twu 4, 5 , Hsiao-Hui Tsou 6, 7 , Po-Ju Lin 8 , Yi-Chun Liu 8 , Jing-Wen Huang 8 , He-Yuan Hsieh 8 , Jin-Ching Lin 5, 8, 9, 10 1 Department of Nursing, Hung Kuang University, Taichung, Taiwan 2 Department of Nursing, National Taichung University of Science and Technology, Taichung, Taiwan 3 Department of Otorhinolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan 4 Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Taiwan 5 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan 6 Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan 7 Graduate Institute of Biostatistics, College of Public Health, China Medical University, Taichung, Taiwan 8 Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan 9 Institute of Clinical Medicine,School of Medicine, National Yang Ming University, Taipei, Taiwan 10 Department of Medicine, China Medical University, Taichung, Taiwan * These authors contributed equally to this work Correspondence to: Jin-Ching Lin, email: jclin@vghtc.gov.tw Keywords: nasopharyngeal carcinoma, radiotherapy, plasma Epstein-Barr virus DNA, quantitative polymerase chain reaction Received: October 25, 2015      Accepted: April 18, 2016      Published: May 12, 2016 ABSTRACT Purpose: To investigate the long-term clinical outcome of nasopharyngeal carcinoma (NPC) patients with persistently detectable plasma EBV (pEBV) DNA after curative radiotherapy (RT). Results: The post-RT pEBV DNA levels were very lower copy number (median 21, interquartile range 8–206 copies/ml). After long-term follow-up, the relapse rate was 64.8%, the median time to progression 20 months, and 5-year overall survival (OS) 49.6%. Thirty-two of 39 (82.1%) patients with high viral load (≥ 100 copies/ ml) developed tumor relapse, whereas 57.0% (49/86) patients with low viral load (< 100 copies/ml) had tumor relapse ( P = 0.0065). The 5-year OS rates were 20.5% and 62.9% for patients with viral load ≥ and < 100 copies/ml (median survival, 20 vs. 100 months; P < 0.0001). Patients who received adjuvant chemotherapy (AdjCT) experienced significant reduction in distant failures (66.2% vs. 31.6%; P = 0.0001) but similar locoregional recurrences ( P = 0.2337). The 5-year OS rates were 69.4% for patients who received AdjCT compared with 33.2% for those of without AdjCT (median survival, 111 vs. 32 months; P < 0.0001). Methods: We screened 931 newly diagnosed NPC patients who finished curative RT and found 125 patients (13.4%) with detectable pEBV DNA one week after RT. The clinical characteristics, treatment modality, subsequent failure patterns and survivals were analyzed. Conclusions: NPC patients with persistently detectable pEBV DNA after curative RT have a higher rate of treatment failure and poor survivals. Levels of the post-RT pEBV DNA and administration of AdjCT affect the final outcome significantly." @default.
• W2348249897 created "2016-06-24" @default.
• W2348249897 creator A5000146658 @default.
• W2348249897 creator A5020328284 @default.
• W2348249897 creator A5029215411 @default.
• W2348249897 creator A5040858214 @default.
• W2348249897 creator A5046489712 @default.
• W2348249897 creator A5055619142 @default.
• W2348249897 creator A5057111962 @default.
• W2348249897 creator A5061190717 @default.
• W2348249897 creator A5085369861 @default.
• W2348249897 date "2016-05-12" @default.
• W2348249897 modified "2023-09-27" @default.
• W2348249897 title "Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA" @default.
• W2348249897 cites W1588533075 @default.
• W2348249897 cites W182988086 @default.
• W2348249897 cites W1968017437 @default.
• W2348249897 cites W1969762178 @default.
• W2348249897 cites W1976270947 @default.
• W2348249897 cites W1976598906 @default.
• W2348249897 cites W1982720422 @default.
• W2348249897 cites W2000617239 @default.
• W2348249897 cites W2003176973 @default.
• W2348249897 cites W2005374110 @default.
• W2348249897 cites W2014401523 @default.
• W2348249897 cites W2035947698 @default.
• W2348249897 cites W2045943543 @default.
• W2348249897 cites W2082933047 @default.
• W2348249897 cites W2086931150 @default.
• W2348249897 cites W2093974625 @default.
• W2348249897 cites W2102310008 @default.
• W2348249897 cites W2125919881 @default.
• W2348249897 cites W2126919372 @default.
• W2348249897 cites W2132871252 @default.
• W2348249897 cites W2135683659 @default.
• W2348249897 cites W2136080892 @default.
• W2348249897 cites W2148900467 @default.
• W2348249897 cites W2149067175 @default.
• W2348249897 cites W2149767124 @default.
• W2348249897 cites W2158776902 @default.
• W2348249897 cites W2160982012 @default.
• W2348249897 cites W2161043223 @default.
• W2348249897 cites W2161296773 @default.
• W2348249897 doi "https://doi.org/10.18632/oncotarget.9323" @default.
• W2348249897 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5173160" @default.
• W2348249897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27191654" @default.
• W2348249897 hasPublicationYear "2016" @default.
• W2348249897 type Work @default.
• W2348249897 sameAs 2348249897 @default.
• W2348249897 citedByCount "29" @default.
• W2348249897 countsByYear W23482498972016 @default.
• W2348249897 countsByYear W23482498972017 @default.
• W2348249897 countsByYear W23482498972018 @default.
• W2348249897 countsByYear W23482498972019 @default.
• W2348249897 countsByYear W23482498972020 @default.
• W2348249897 countsByYear W23482498972021 @default.
• W2348249897 countsByYear W23482498972022 @default.
• W2348249897 countsByYear W23482498972023 @default.
• W2348249897 crossrefType "journal-article" @default.
• W2348249897 hasAuthorship W2348249897A5000146658 @default.
• W2348249897 hasAuthorship W2348249897A5020328284 @default.
• W2348249897 hasAuthorship W2348249897A5029215411 @default.
• W2348249897 hasAuthorship W2348249897A5040858214 @default.
• W2348249897 hasAuthorship W2348249897A5046489712 @default.
• W2348249897 hasAuthorship W2348249897A5055619142 @default.
• W2348249897 hasAuthorship W2348249897A5057111962 @default.
• W2348249897 hasAuthorship W2348249897A5061190717 @default.
• W2348249897 hasAuthorship W2348249897A5085369861 @default.
• W2348249897 hasBestOaLocation W23482498971 @default.
• W2348249897 hasConcept C108516343 @default.
• W2348249897 hasConcept C119060515 @default.
• W2348249897 hasConcept C126322002 @default.
• W2348249897 hasConcept C138816342 @default.
• W2348249897 hasConcept C141071460 @default.
• W2348249897 hasConcept C142724271 @default.
• W2348249897 hasConcept C143998085 @default.
• W2348249897 hasConcept C2778997737 @default.
• W2348249897 hasConcept C2908647359 @default.
• W2348249897 hasConcept C509974204 @default.
• W2348249897 hasConcept C512399662 @default.
• W2348249897 hasConcept C71924100 @default.
• W2348249897 hasConcept C99454951 @default.
• W2348249897 hasConceptScore W2348249897C108516343 @default.
• W2348249897 hasConceptScore W2348249897C119060515 @default.
• W2348249897 hasConceptScore W2348249897C126322002 @default.
• W2348249897 hasConceptScore W2348249897C138816342 @default.
• W2348249897 hasConceptScore W2348249897C141071460 @default.
• W2348249897 hasConceptScore W2348249897C142724271 @default.
• W2348249897 hasConceptScore W2348249897C143998085 @default.
• W2348249897 hasConceptScore W2348249897C2778997737 @default.
• W2348249897 hasConceptScore W2348249897C2908647359 @default.
• W2348249897 hasConceptScore W2348249897C509974204 @default.
• W2348249897 hasConceptScore W2348249897C512399662 @default.
• W2348249897 hasConceptScore W2348249897C71924100 @default.
• W2348249897 hasConceptScore W2348249897C99454951 @default.
• W2348249897 hasIssue "27" @default.
• W2348249897 hasLocation W23482498971 @default.
• W2348249897 hasLocation W23482498972 @default.

• next